Alexion Pharmaceuticals Inc. Release: Soliris® Significantly Improved Clinical Outcomes in Patients With aHUS in Pivotal Trials Published in New England Journal of Medicine

Published: Jun 06, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data published in the June 6 issue of The New England Journal of Medicine (NEJM) demonstrate that chronic Soliris® (eculizumab) therapy is effective in the treatment of patients with atypical hemolytic uremic syndrome (aHUS), a genetic, life-long, ultra-rare disease associated with vital organ failure and premature death.1 In patients with aHUS, uncontrolled terminal complement activation causes thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body.2,3

Help employers find you! Check out all the jobs and post your resume.

Back to news